Cellbox Solutions, a Cologne-based warm-chain logistics technology company enabling the global transport of living cells under controlled physiological conditions, has raised €3.5 million in a Series A financing – which remains open for other tranches until May 2026.
The round is led by the digital business angel network Companisto, together with existing investors, including NRW.BANK. The new capital will be used to expand international production and sales activities and to unlock additional application areas, particularly in cell and gene therapy as well as in vitro fertilization (IVF).
“Our vision is to redefine how living cells are transported globally. With the continued support of our investors and the strengthening of our leadership team with a highly experienced executive, we are building the foundation for long-term international growth and expanding the reach of warm-chain logistics across clinical and research applications. We are convinced that reliable live-cell transport will become an essential component of the global life sciences value chain,” says Prof Dr Kathrin Adlkofer, Founder and CEO of Cellbox.
Recent EU-Startups coverage shows continued investment across the European ecosystem supporting cell-based therapies, advanced biomanufacturing, and enabling life sciences technologies.
For example, UK startup Tozaro secured €6.9 million to expand partnerships and further develop its Smart Polymer platform designed to reduce the cost of cell and gene therapy production. In the Netherlands, QT Sense raised €4 million to advance a quantum sensing platform that allows researchers to monitor cellular stress in real time, supporting biomedical and drug development research.
Meanwhile, Sweden’s Cellcolabs secured €10.3 million to scale manufacturing capacity for stem cell therapies and expand global commercialisation efforts, while Finland-based StemSight raised €2.3 million to advance stem-cell-based treatments for severe blindness towards clinical development. In France, biotech company baCta secured €7 million to scale its platform using programmable microorganisms as molecular factories for industrial and life sciences applications.
Taken together, these rounds represent over €33 million in disclosed funding across adjacent life sciences and biotechnology sectors in 2025–2026.
Within this broader landscape, Cellbox Solutions operates in a complementary segment of the value chain, focusing on the logistics infrastructure required for transporting living cells under physiological conditions – an area expected to become increasingly important as cell and gene therapies move toward larger-scale clinical and commercial deployment.
“Cellbox addresses a structural gap in the life sciences value chain: the reliable transport of living cells at physiological conditions. As advanced therapies scale globally, logistics becomes a critical success factor. We view Cellbox not as an incremental product innovation, but as a scalable platform with the potential to redefine how sensitive biological materials are transported across research and clinical environments,” adds Dr Robin Ghosh, Investment Manager at Companisto.
Founded in 2017, Cellbox Solutions is a warm-chain logistics technology company providing innovative solutions for the global healthcare and life sciences industries to transport sensitive biological materials and therapeutics that cannot be frozen and require controlled physiological conditions.
The company’s portable CO₂ incubator platform, Cellbox, creates a regulated environment for the transport of living cells, organoids, tissues, and other advanced biological materials. Temperature and CO₂ levels are individually adjustable to ensure reproducible incubation conditions throughout shipment.
Its warm-chain technology enables continuously controlled shipment conditions for up to 48 hours, preserving cell viability and functionality during transport.
A key component of this next growth phase is the appointment of Dr Bernd Muehlenweg as CBO and CFO of Cellbox.
“Cellbox is setting a new benchmark in the transportation of living cells. By enabling safe, controlled, and reproducible transport under physiological conditions, we address a critical bottleneck in the life sciences industry. The investment round marks an important milestone in expanding our international footprint and establishing Cellbox as a global infrastructure standard for living cell shipment and warm-chain logistics.
“Our patented platform and strong regulatory positioning provide an excellent foundation for global scale-up across multiple life sciences applications, including the rapidly growing field of cell and gene therapies. I look forward to further strengthening our commercial operations, expanding our service portfolio, and building the organisational structures required to support the next phase of international growth,” says Dr Bernd Muehlenweg, CBO and CFO of Cellbox Solutions GmbH.
In the long term, Cellbox aims to establish warm-chain logistics as the preferred global approach for transporting living cells, cell therapies, and sensitive biological materials, further advancing reliability and reproducibility across the life sciences sector.
Read the orginal article: https://www.eu-startups.com/2026/03/germanys-cellbox-solutions-raises-e3-5-million-to-expand-global-transport-technology-for-living-cells/
